Sign Up Today and Learn More About Inscripta Stock
Invest in or calculate the value of your shares in Inscripta or other pre-IPO companies through EquityZen's platform.
Inscripta Stock (INSC)
Inscripta is a gene editing technology company.
Inscripta is a gene-editing technology company.
About Inscripta Stock
Founded
2015
Headquarters
Boulder, CO, US
Total Funding
84.5M
Industries
Software, Artificial Intelligence, Data and Analytics
Inscripta is a gene-editing technology company that puts researchers in control by making it easy for them to get all they need for cutting-edge, forward cell-engineering. These tools include a family of CRISPR enzymes (called MADzymes), custom nucleases for researchers and commercial partners, and a full suite of gene-editing tools (instruments, reagents, and software) that will significantly increase the speed and efficiency of multiplexed, precision gene editing. By removing the barriers to forward cell engineering and gene-editing research, Inscripta will usher in a new era of advances to revolutionize how we feed, fuel, and heal humanity. Inscripta is led by several genomic technology veterans including CEO Kevin Ness, who co-founded QuantaLife and 10x Genomics, and John Stuelpnagel, the chairman of the company's board, who was co-founder and first CEO of Illumina and chairman of 10x Genomics. Inscripta is headquartered in Boulder, Colo.; has offices in Pleasanton, Calif.; and is backed by Venrock, MLS Capital, NanoDimension, Foresite, Paladin Capital Group, and MĂ©rieux DĂ©veloppement.
Inscripta Press Mentions
Stay in the know about the latest news on Inscripta
Prime Editing and CRISPR Market Worth USD 23.493 Billion by 2030 at a CAGR of 24.3%
einpresswire • Aug 13, 2025
Prime Editing and CRISPR Market Worth USD 23.493 Billion by 2030 at a CAGR of 24.3%
einpresswire • Jul 14, 2025
Digital Genome Market Projected To Witness Substantial Growth, 2025-2032: GenMark Diagnostics, Inc., Inscripta, Inc
einpresswire • Mar 01, 2025
Synthetic Biology Market Worth $12.33 Billion in 2024, is Forecast to Generate Revenues of $31.52 Billion by 2029, Witnessing 20.6% CAGR
globenewswire • Dec 13, 2024
Prime Editing and CRISPR Market Estimation Worth $23.49 Billion by 2030
einpresswire • Dec 09, 2024
Investors in Inscripta
Discover investors in Inscripta stock and explore their portfolio companies
Inscripta Management
Leadership team at Inscripta
General Counsel
Dianna DeVore
VP Finance
Eric Warnecke
Join now and verify your accreditation status to gain access to:
- Inscripta Current Valuation
- Inscripta Stock Price
- Inscripta Management
- Available deals in Inscripta and all other companies with relevant Deal Offering documents
- EquityZen's proprietary data and insights, which may include
- Inscripta Cap Table and Funding History by Share Class and Liquidity Preferences
- Inscripta Revenue and Financials
- Inscripta Highlights
- Inscripta Business Model
- Inscripta Risk Factors
- Inscripta Research Report from SACRA Research
Key Facts
Trading Stock
How to invest in stock?
Accredited investors are able to buy pre-IPO stock through online marketplaces like EquityZen funds. These shares are made available by existing shareholders and are traded subject to market availablity. and compliance with securities regulations
How to sell stock?
Shareholders can sell their stock through EquityZen's private company marketplace. EquityZen's network includes accredited investors interested in buying private company stock. Learn more about the Shareholder liquidity process.
If I invest, how do I exit my investment?
There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. See more information on Express Deals and pre-IPO exit information.
Why choose EquityZen?
Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds, EquityZen leads the way in delivering "Private Markets for the Public."
